a Johns Hopkins University School of Medicine , Baltimore , MD , USA.
b Beth Israel Deaconess Medical Center, Harvard Medical School , Boston , MA , USA.
Expert Rev Respir Med. 2018 Jul;12(7):605-614. doi: 10.1080/17476348.2018.1486709. Epub 2018 Jun 19.
Lung cancer is the leading cause of cancer-related deaths in the United States. Nearly 85% of all lung cancers are diagnosed at a late stage, with an associated five-year survival rate of 4%. Malignant central airway obstruction and malignant pleural effusions occur in upwards of 30% of these patients. Many of these patients are in need of palliative interventions for symptom control and to help improve their quality of life. Areas covered: This review covers the treatment modalities of malignant central airway obstruction and malignant pleural effusion. PubMed was used to search for the most up to date and clinically relevant articles that guide current treatment strategies. This review focuses on rigid bronchoscopy and the tools used for the relief of central airway obstruction, as well as intra-pleural catheter use and pleurodesis for the management of malignant pleural effusions. Expert commentary: There are multiple treatment modalities that may be used to help alleviate the symptoms of malignant central airway obstruction and pleural effusion. The modality used depends on the urgency of the situation, and specific patient's goals. An open dialog to understand the patient's end of life goals is an important factor when choosing the appropriate treatment strategy.
肺癌是美国癌症相关死亡的主要原因。几乎所有肺癌的诊断都处于晚期,五年生存率为 4%。超过 30%的这些患者发生恶性中央气道阻塞和恶性胸腔积液。为了控制症状和提高生活质量,许多患者需要姑息性治疗干预。涵盖领域:本综述涵盖了恶性中央气道阻塞和恶性胸腔积液的治疗方法。使用 PubMed 搜索了最新的、最具临床相关性的指导当前治疗策略的文章。本综述重点介绍了用于缓解中央气道阻塞的刚性支气管镜和工具,以及用于恶性胸腔积液管理的胸腔内导管使用和胸膜固定术。专家评论:有多种治疗方法可用于缓解恶性中央气道阻塞和胸腔积液的症状。所使用的方法取决于情况的紧急程度和特定患者的目标。在选择适当的治疗策略时,与患者进行开放对话以了解其临终目标是一个重要因素。